Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Guselkumab - Janssen Biotech

Next Previous
X
Search
Drug Profile

Guselkumab - Janssen Biotech

Alternative Names: CNTO-1959; TREMFYA; TREMFYA ONE-PRESS

Latest Information Update: 13 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; MorphoSys; Taiho Pharmaceutical
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Palmoplantar pustulosis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Registered Ulcerative colitis
  • Preregistration Crohn's disease
  • Phase III Psoriasis
  • Phase II Giant cell arteritis; Hidradenitis suppurativa; Lupus nephritis; Systemic scleroderma
  • Phase I Familial adenomatous polyposis
  • Discontinued Coeliac disease; Rheumatoid arthritis

Most Recent Events

  • 11 Sep 2024 Registered for Ulcerative colitis (In adults) in USA (IV)
  • 06 Aug 2024 Janssen Research & Development completes a phase II AFFINITY trial in Psoriatic arthritis (Combination therapy, Treatment experienced) in USA, Ukraine, Sweden, Russia, Poland, Italy, Hungary, France, Denmark and Spain (SC, Injection) (EudraCT2021-002012-31; NCT05071664)
  • 27 Jun 2024 Celsius Therapeutics has been acquired and merged into AbbVie

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top